• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kiniksa Pharmaceuticals International plc

    7/9/25 4:06:03 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Kiniksa Pharmaceuticals International, plc

    (Name of Issuer)


    Class A Ordinary Shares, nominal value $0.000273235 per share

    (Title of Class of Securities)


    G52694109

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G52694109


    1Names of Reporting Persons

    RUBRIC CAPITAL MANAGEMENT LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,909,806.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,909,806.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,909,806.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.24 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    G52694109


    1Names of Reporting Persons

    DAVID ROSEN
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,909,806.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,909,806.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,909,806.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.24 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Kiniksa Pharmaceuticals International, plc
    (b)Address of issuer's principal executive offices:

    23 Old Bond Street, Floor 3 London, X0, W1S 4PZ
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the shares of Class A ordinary shares, nominal value $0.000273235 per share (the "Class A Ordinary Shares") of Kiniksa Pharmaceuticals International, plc, a public limited company incorporated in England and Wales (the "Issuer") reported herein; and (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.
    (c)Citizenship:

    Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.
    (d)Title of class of securities:

    Class A Ordinary Shares, nominal value $0.000273235 per share
    (e)CUSIP No.:

    G52694109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) - (c) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover page for each of the Reporting Persons and in Item 4(b) is based on the 42,336,227 Class A Ordinary Shares outstanding as of April 25, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 filed with the Securities and Exchange Commission on April 29, 2025.
    (b)Percent of class:

    9.24  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Class A Ordinary Shares.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RUBRIC CAPITAL MANAGEMENT LP
     
    Signature:/s/ Michael Nachmani
    Name/Title:Michael Nachmani / Chief Operating Officer
    Date:07/09/2025
     
    DAVID ROSEN
     
    Signature:/s/ David Rosen
    Name/Title:David Rosen / Individually
    Date:07/09/2025
    Get the next $KNSA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

      – KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and webcast at Jefferies 2025 Global Healthcare Conference scheduled for 12:50 pm ET today– LONDON, June 05, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today announced details for its planned Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, expected to initiate in the middle of 2025. KPL-387 i

      6/5/25 7:00:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

      LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) today announced that management will present at the following investor conferences in June: Jefferies 2025 Global Healthcare Conference on Thursday, June 5 at 12:50 p.m. Eastern TimeGoldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10 at 8:00 a.m. Eastern Time – Fireside Chat A live webcast of Kiniksa's presentations will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. A replay of the events will also be available on Kiniksa's website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceuti

      5/29/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

      – Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed – LONDON, April 30, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, has partnered with Country Music Association, Academy of Country Music, and GRAMMY Award-winning country star, Carly Pearce, to share her personal experience with recurrent

      4/30/25 8:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      3/13/25 7:43:42 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      9/13/24 7:34:05 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Kiniksa Pharmaceuticals with a rating of Overweight and set a new price target of $34.00

      5/3/24 11:21:30 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Levy Richard S converted options into 1,101 units of Class A Ordinary Share, increasing direct ownership by 6% to 18,474 units (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      7/3/25 4:39:40 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $489,244 worth of Class A Ordinary Share (17,300 units at $28.28), decreasing direct ownership by 15% to 61,563 units (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      6/18/25 4:39:56 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Quart Barry D exercised 27,448 units of Class A Ordinary Share at a strike of $3.80 and sold $833,001 worth of Class A Ordinary Share (27,448 units at $30.35) (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      6/11/25 5:35:55 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kiniksa Pharmaceuticals International plc

      SCHEDULE 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      7/9/25 4:06:03 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

      144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      6/9/25 5:08:24 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

      6/5/25 7:10:35 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:32:31 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:15:22 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/13/24 4:30:25 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Financials

    Live finance-specific insights

    See more
    • Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

      4/29/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

      LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and

      4/24/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Abiprubart development in Sjögren's Disease to be discontinued –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and c

      2/25/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care